muc1 vaccine for triple-negative breast cancer

Conditions: Breast Cancer; Inflammatory Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer

Summary: rationale: vaccines made from peptides may help the body build an effective immune response to kill tumor cells. giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer. purpose: to evaluate the efficacy of poly-iclc + muci peptide vaccine in boosting the immunologic response to muci in patients with triple-negative bc

primary objectives: i. to evaluate the efficacy of muc1 peptide-poly-iclc adjuvant vaccine in boosting systemic immunity to muc1 in women who have completed therapy for ajcc(american joint committee on cancer)stage i-iii 'triple-negative' \[i.e., er(-) pr(-) her2/neu(-)\] breast cancer. secondary objectives: i. to evaluate the safety and toxicity of the muc1 peptide and poly-iclc vaccine in this cohort of patients. outline: patients receive muc-1 peptide vaccine subcutaneously (sc) and poly-iclc vaccine sc in weeks 0, 2, and 10 in the absence of disease progression or unacceptable toxicity. some patients may receive a booster vaccine in week 52. patients will be followed for study-related serious adverse events (saes) for a period of 30 days after their last vaccination. if a patient experiences a sae while participating in this study, they will be followed until the resolution of the sae.

Eligibility criteria:
inclusion criteria: * ajcc stage i-iii infiltrating adenocarcinoma of the breast who have completed standard adjuvant or neoadjuvant therapy (surgery, radiation, biologic therapy, chemotherapy) for tnbc (er-, pr-, her-2/neu-) * patients who have completed standard therapy for triple-negative inflammatory bc are eligible * eastern cooperative oncology group (ecog) performance status 0-1 * absolute neutrophil count \>= 1,000/mm\^3 * hemoglobin \>= 10.0 g/dl * platelet count \>= 100,000/mm\^3 * total bilirubin must be within normal limits * transaminases (aspartate aminotransferase \[ast\] and/or alanine aminotransferase \[alt\]) may be up to 2.5 x institutional upper limit of normal (uln) if alkaline phosphatase is =\< uln * alkaline phosphatase may be up to 4 x uln if transaminases are =\< uln * normal creatinine and blood urea nitrogen (bun); if abnormal, calculated creatinine clearance must be \>= 60 mg/dl * human immunodeficiency virus (hiv)(-), antinuclear antibody (ana)(-), hepatitis panel (-), normal thyroid function tests; these tests will be performed at the discretion of the investigator if warranted by history or clinical presentation * patients must be disease-free of prior invasive malignancies for \>= 5 years, with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix * all patients must have completed surgery with sentinel and/or axillary lymph node dissection according to participating institutional guidelines * all patients must have completed adjuvant radiation therapy according to participating institutional guidelines * all patients must have completed either adjuvant or neoadjuvant chemotherapy according to participating institutional guidelines; the choice of chemotherapy is at the discretion of the treating physician * women of childbearing potential must have a negative pregnancy test and must be willing to consent to using an accepted and effective barrier form method of contraception during participation in the study and for a reasonable period thereafter * patients must provide written informed consent exclusion criteria: * known metastatic bc * radiotherapy, chemotherapy, biologic therapy, or other investigational therapy within the preceding 4 weeks * previous splenectomy or radiotherapy to spleen * coexisting or previous malignancies except carcinoma in situ of the cervix or basal cell carcinoma of the skin * active or uncontrolled infection * psychiatric, addictive, or any disorder that compromises the ability to give informed consent to participate in or to comply with the requirements of the study * concurrent systemic corticosteroid treatment - must be off all steroids for at least 4 weeks prior to vaccine administration * any condition or behavior that in the judgment of the investigator, would compromise the patient's ability to participate in the study